Johnson & Johnson Innovation Plans Research Center In New York City
The 30,000-square foot facility will be located at the New York Genome Center in the SoHo section of Manhattan and open in 2018. As an incentive, the project is receiving $17 million in New York State funding. The site will be open to biotech, pharmaceutical, medical device and consumer health companies, particularly startups working on cross-sector solutions to prevent, intercept or cure diseases.
"Expanding the JLABS model to New York City, home to world-class academic and medical institutions, furthers Johnson & Johnson Innovation's commitment to providing resources that catalyze and foster the growth of life science ecosystems around the world," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "Our hope is that JLABS @ NYC will provide a resource-rich environment for innovators throughout the New York region where today's ideas can become healthcare products that truly impact patient's lives."
JLABS, in addition to offering emerging life science companies modular lab units, office space, shared core laboratory equipment and business facilities, will link the entrepreneurs of New York with the full breadth of Johnson & Johnson Innovation, including opportunities for funding, third-party services, educational events and R&D experts from medical technology, consumer healthcare product and Janssen pharmaceutical teams.
"The ever-evolving life science sector is discovering solutions to the most pressing problems of our time, helping to cure disease and save lives around the world," said Governor Andrew Cuomo. "New York is poised to be a global leader in this industry, and the new, vital incubator JLABS will be the catalyst that pushes our state into the forefront of this exciting field.”
"The New York Genome Center is excited to be a partner with Johnson & Johnson Innovation, Governor Cuomo and New York State in bringing JLABS to New York," said NYGC President & COO Cheryl A. Moore. "JLABS' support of talented scientists in New York as they take their innovative ideas to market aligns with our mission of fostering intellectually vibrant collaborations that advance the development of new treatments, therapies and therapeutics against human disease."
Germany-Based Fresenius Kabi Plans Regional Distribution Hub in Pleasant Prairie, Wisconsin
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
A Changing Food Manufacturing Industry
2017 Food Processing
2018 Leading Metro Locations: Pacific and Mountain Metros Dominate the List
33rd Annual Corporate Survey & the 15th Annual Consultants Survey
What Makes a Successful Innovation District?